Latest News

7 April 2014

Starpharma expands its Drug Delivery Program with AstraZeneca

Starpharma today announced the signing of a second, expanded agreement with AstraZeneca in the field of cancer medicine using Starpharma’s proprietary DEP™ dendrimer drug delivery technology.

The agreement follows on from an evaluation by AstraZeneca which began in September 2012 of Starpharma’s delivery technology. The new agreement will see the application of Starpharma’s technology to a cancer drug, from AstraZeneca’s pipeline.

Read more

14 March 2014

VivaGel®-coated condom approved for marketing in Japan

Starpharma today announced that regulatory certification has been granted for marketing Starpharma’s VivaGel®-coated condom in Japan, the world’s second largest condom market. VivaGel® is licensed to Okamoto as a condom coating for the Japanese market. Okamoto is the market leader for condoms sold in Japan and has held this position for many years.

Read more

11 March 2014

Starpharma receives $4.7M R&D tax incentives

Starpharma today announced it has received the anticipated $4.7M of R&D tax incentive relating to FY13 expenditures, following the lodgement of the Company’s annual income tax return.

Read more

23 January 2014

Starpharma commences Dendrimer-Docetaxel clinical trial

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel. 

The trial will be conducted exclusively in Australia, at Nucleus Network's clinical facility at the AMREP/Alfred Hospital initially, with the plan to add 1 to 2 additional sites in the near future. 

Read more

In the media

10 April 2014

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Thursday 10 April 2014. With the biotechnology sector predicted to offer some of the best growth, Ticky discussed the newly announced expansion of Starpharma’s drug delivery platform, the receipt of $4.7M of R&D tax incentives and its benefits for the Australian biotechnology industry and more Australian-based clinical trials.


Watch the video (external link)

20 November 2013

Australian Financial Review: Biotech sector revival as appetite for risk grows

Australian Financial Review Journalist, Bina Brown reported on an Australian equities market shift away from resources into biotech and included Starpharma as a company to watch. The article noted the recent positive data showing that the Company’s delivery technology can make commonly use cancer drugs work a lot better as well as reduce side effects that can result in patients having to stop treatment.

 “[Starpharma’s] delivery technology can not only make commonly used cancer drugs work a lot better, but can get rid of the main side-effects that can mean cancer patients have to stop using them.. ‘If the human data is anything like what we have seen in preclinical ­studies, this will be a total game changer.’”

16 October 2013

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Wednesday 16th October 2013. Ticky discussed the positive results of Starpharma’s dendrimer version of oxaliplatin.

 

 Watch the video (external link)

16 October 2013

Sky Business News: Interview with Starpharma CEO Jackie Fairley

Starpharma CEO Dr Jackie Fairley joined Sky News to discuss the positive results of the Company’s pre-clinical trial of Dendrimer-Enhanced Oxaliplatin. Starpharma’s dendrimer version of the blockbuster colon and colorectal cancer drug was shown to be less neurotoxic than conventional oxaliplatin.

 

View the Interview

Shareholder Updates

17 December 2013

Shareholder Update: December 2013

In this issue:

› Dendrimer-Docetaxel to enter human clinical trials

› VivaGel® Phase 3 trial for prevention of recurrent BV

› VivaGel®-coated condom: Consumer feedback

› Impressive results for Dendrimer-Enhanced Oxaliplatin

› Progress continues in agrochemical activities

› Appointment of Rob Thomas

› SPL TV – a new channel

 

Download: Shareholder Update: December 2013 ( pdf file, 1MB)

24 May 2013

Shareholder Update: May 2013

In this issue:

›  VivaGel® update

› New agrochemical partnership

› SPL7013 shows therapeutic potential in viral conjunctivitis

› Positive dendrimer-doxorubicin results

› Key patents obtained

› R&D tax refund received

› Momentum builds in nanomedicine

› Substantial holders increase their stake

Download: Shareholder Update: May 2013 ( pdf file, 1MB)

Sign up to receive news here

© Starpharma Holdings Limited 2014